The antioxidant effects of Q10 co enzyme on oxidative stress and lipid per oxidation among gastric patients infected by h.pylori

• Register: IRCT
• Last refreshed on: 22 February 2018
• Main ID: IRCT2014070118310N1
• Date of registration: 2014-09-10
• Prospective Registration: No
• Primary sponsor: Vice Chancellor for researchesand Technology, Ilam University of Medical Sciences
• Public title: The antioxidant effects of Q10 co enzyme on oxidative stress and lipid per oxidation among gastric patients infected by h.pylori
• Scientific title: Anti oxidant properties of Q10 co enzyme and their effects on oxidative stress and lipid per oxidation among patients infected by h. pylori
• Date of first enrolment: 2014-06-22
• Target sample size: 100
• Recruitment status: Complete
• URL: http://en.irct.ir/trial/16638
• Study type: interventional
• Study design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.
• Phase: N/A

Countries of recruitment

Iran (Islamic Republic of)

Contacts

• Name: Dr Asadollahi Khairollah
• Affiliation: Ilam University of Medical Sciences

• Name: Dr Asadollahi Ruhangiz
• Affiliation: Ilam University of Medical Sciences

Key inclusion & exclusion criteria

Inclusion criteria: Including criteria: h. pylori infected gastric patients
Excluding criteria: pregnancy; lactation; recent antibiotic application (6 recent weeks); recent attempt for h. pylori treatment; recent surgery of stomach; positive history of alcohol consumption or addiction; having infections or malignancies in other organs; cardiovascular diseases; diabetes; IBD .
Exclusion criteria:

Age minimum: no limit
Age maximum: no limit
Gender: Both

Health Condition(s) or Problem(s) studied

Chronic gastritis, unspecified

Gastritis.
Chronic gastritis, unspecified

k 29.5

Intervention(s)

Intervention 1: Intervention group: Using three drugs regimen (bismuth sub citrate (120mg/kg QD), tetracycline (500mg QD) and metronidazole (400 mg/kg TD)) + Q10 coenzyme (2 mg/kg/day) for 6 weeks.
The types and dosages of drugs are not changed during treatment period. Intervention 2: Control group: Using three drugs regimen (bismuth sub citrate (120mg/kg QD), tetracycline (500mg QD) and metronidazole (400 mg/kg TD)) + placebo (lactolose) for 6 weeks.
The types and dosages of drugs are not changed during treatment period.

Intervention group: Using three drugs regimen (bismuth sub citrate (120mg/kg QD), tetracycline (500mg QD) and metronidazole (400 mg/kg TD)) + Q10 coenzyme (2 mg/kg/day) for 6 weeks.
The types and dosages of drugs are not changed during treatment period.

Control group: Using three drugs regimen (bismuth sub citrate (120mg/kg QD), tetracycline (500mg QD) and metronidazole (400 mg/kg TD)) + placebo (lactolose) for 6 weeks.
The types and dosages of drugs are not changed during treatment period.

Treatment - Drugs

Primary Outcome(s)

Glutation peroxidise. Timepoint: Start and end of study. Method of measurement: Serum level of studied marker by standard kits.

Malondialdehyde. Timepoint: Start and end of study. Method of measurement: Serum level of studied marker by standard kits.

Total antioxidant capacity (TAC). Timepoint: Start and end of study. Method of measurement: Serum level of studied marker by standard kits.

Source(s) of Monetary Support

Vice Chancellor for researchesand Technology, Ilam University of Medical Sciences

Ethics review

Status: Approved
Approval date:
Contact:

?Ethics committee of Ilam University of Medical Sciences